Pricing and reimbursement delays continue to impact biopharma revenue streams

Core Insights - Delays in pricing and reimbursement (P&R) processes are significant hurdles for the pharmaceutical industry, as highlighted by a survey from GlobalData's State of the Biopharmaceutical Industry report [1] Group 1: Impact of P&R Processes - Industry professionals rated the negative impact of P&R delays on business at 3.7 points on a scale of 1-5, indicating a substantial concern [2] - 22% of survey respondents identified P&R constraints as the most negative factor affecting their business in the next 12 months, second only to political and trade issues [3] Group 2: Pricing Pressures - Drug pricing has become a critical issue due to global inflation and geopolitical factors increasing development and commercialization costs [4] - The top three regulatory and macroeconomic trends negatively affecting the industry are all related to pharmaceutical pricing [5] - Key trends impacting drug pricing include inflation, the Inflation Reduction Act (IRA), the Most Favored Nation (MFN) policy, and International Referencing Pricing (IRP) [6] Group 3: Global Implications - Pricing pressures in the US may have global repercussions due to the use of IRP, which references lower drug prices from countries with lower GDP per capita [7] - This referencing can hinder the accessibility and affordability of medicines, potentially leading to delayed or canceled product launches [7]